5-azacytidine
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
cc-5013 National Cancer Institute (NCI) | Phase 2 | BBB |
Nivolumab Mayo Clinic | Phase 2 | B |
Parsaclisib Walter Hanel | Phase 1 | CC |
FLUDEOXYGLUCOSE Mayo Clinic | Phase 1 | CC |
DARATUMUMAB Mayo Clinic | Phase 1 | CC |
View all 12 →
Same molecule, other indications
5-azacytidine is also rated in:
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →